Ishara Investments LP Purchases New Shares in Zentalis Pharmaceuticals, Inc. $ZNTL

Ishara Investments LP purchased a new stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,320,000 shares of the company’s stock, valued at approximately $1,782,000. Zentalis Pharmaceuticals makes up about 2.1% of Ishara Investments LP’s investment portfolio, making the stock its 17th biggest position.

A number of other hedge funds also recently bought and sold shares of ZNTL. Barr E S & Co. raised its stake in shares of Zentalis Pharmaceuticals by 43.8% in the fourth quarter. Barr E S & Co. now owns 57,500 shares of the company’s stock valued at $78,000 after acquiring an additional 17,500 shares during the period. Vanguard Group Inc. raised its stake in shares of Zentalis Pharmaceuticals by 0.7% in the third quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock valued at $4,386,000 after acquiring an additional 19,768 shares during the period. Sivia Capital Partners LLC purchased a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter valued at $27,000. Quarry LP raised its stake in shares of Zentalis Pharmaceuticals by 21.4% in the fourth quarter. Quarry LP now owns 132,000 shares of the company’s stock valued at $178,000 after acquiring an additional 23,250 shares during the period. Finally, Qube Research & Technologies Ltd raised its stake in shares of Zentalis Pharmaceuticals by 76.4% in the third quarter. Qube Research & Technologies Ltd now owns 56,639 shares of the company’s stock valued at $86,000 after acquiring an additional 24,526 shares during the period.

Zentalis Pharmaceuticals Trading Up 2.8%

NASDAQ ZNTL opened at $3.62 on Thursday. The company’s 50-day moving average price is $4.07 and its 200-day moving average price is $2.90. The stock has a market cap of $257.71 million, a PE ratio of -2.09 and a beta of 1.96. Zentalis Pharmaceuticals, Inc. has a 12 month low of $1.13 and a 12 month high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01). As a group, sell-side analysts forecast that Zentalis Pharmaceuticals, Inc. will post -1.92 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on ZNTL. Guggenheim increased their target price on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, April 10th. Wall Street Zen raised shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Tuesday, April 7th. Wells Fargo & Company began coverage on shares of Zentalis Pharmaceuticals in a research note on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $5.83.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.